Media | Contact us

About us
Protecting our tomorrow
A firm focus on vaccines stands at the core of everything we do.
READ MORE
At a glance
Our Leadership Team
Governance
Business Ethics
Sustainability
What we do
From R&D to manufacturing
We are focused on the research, development and manufacturing of innovative life-saving vaccines
READ MORE
Products
Pipeline
INVESTORS
Investors
We are committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more
Annual Report 2023
News
Events & Presentations
Financials
Stock information
Analysts
Annual General Meeting
Shareholder Portal
FAQ
Careers
Careers
We offer a challenging international working environment in which job satisfaction and personal growth have a high priority.
READ MORE
Working With Us
Job Openings
Our Employees

Consensus

Bavarian Nordic collected consensus estimates prior to Q3 2024 results.

	Consensus
DKK, million	Q3 2024	2024
Sale of goods	1,574	5,579
Public Preparedness (Jynneos/IMVANEX/IMVAMUNE)	880	3,385
Travel Health	694	2,194
Sale of services	46	193
Total revenue	1,620	5,772
EBITDA	521	1,685

Number of participants: 5 analysts